:Serinolamide A

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = (R,E)-N-(1-Hydroxy-3-methoxypropan-2-yl)-N-methyloctadec-4-enamide

| image = Serinolamide A.svg

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1342300-14-4

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 7AX37Z58VV

| ATC_prefix =

| ATC_suffix =

| PubChem = 56597771

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID = 27025743

| C=23 | H=45 | N=1 | O=3

| smiles = O=C(N(C)[C@H](CO)COC)CC/C=C/CCCCCCCCCCCCC

| StdInChI = 1S/C23H45NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24(2)22(20-25)21-27-3/h16-17,22,25H,4-15,18-21H2,1-3H3/b17-16+/t22-/m1/s1

| StdInChIKey = CJAVPRNATZCNLN-NBRGKURFSA-N

}}

Serinolamide A is a naturally occurring eicosanoid derivative related to anandamide, which has been isolated from the marine cyanobacteria Lyngbya majuscula and related species in the Oscillatoria family.

Testing established that serinolamide A is an active cannabinoid agonist with moderate potency, having a K_i of 1300 nM at CB₁ and five fold selectivity over the related CB₂ receptor.{{cite journal | vauthors = Gutiérrez M, Pereira AR, Debonsi HM, Ligresti A, Di Marzo V, Gerwick WH | title = Cannabinomimetic lipid from a marine cyanobacterium | journal = Journal of Natural Products | volume = 74 | issue = 10 | pages = 2313–7 | date = October 2011 | pmid = 21999614 | pmc = 3325759 | doi = 10.1021/np200610t }}